ArticlePharmaceuticals (Basel, Switzerland)2022

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells.

Yuelong Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.